UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13A-17 OR 15D-17 THEREUNDER
The Liposome Company, Inc.
(Exact name of issuer as specified in charter)
One Research Way, Princeton Forrestal Center, Princeton, NJ 08540
(Address of principal Executive offices)
Issuer's telephone number, including area code (609) 452-7060
CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of Security
Common Stock, par value $.01 per share
2. Number of shares
outstanding before the change 27,274,962
3. Number of shares
outstanding after the change 27,724,962
4. Effective date of
change April 27, 1995 (date of SEC order of effectiveness)
May 26, 1995 (closing date)
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.) Distribution
Give brief description of transaction Public offering of Common Stock
pursuant to
Registration No. 33-58169
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
2. Name after change
3. Effective date of
charter amendment changing name
4. Date of shareholder
approval of change, if required
Date June 5, 1995
(Officer's signature & title)
Vice President, General Counsel and Secretary
VIA FEDERAL EXPRESS
June 5, 1995
Ms. Joan O'Kane
NASDAQ Operations
National Association of Securities Dealers, Inc.
1735 K Street, N.W.
Washington, D.C. 20006
Dear Ms. O'Kane:
Subject: Form 10-C - The Liposome Company, Inc.
Enclosed you will find Form 10-C for the issuance of additional shares of Common
Stock of The Liposome Company, Inc., effective May 26, 1995,as filed via Edgar
Link with the SEC.
Sincerely yours,
THE LIPOSOME COMPANY, INC.
Carol J. Gillespie
Vice President, General Counsel and
Secretary
Enclosures
10C-2.sec
